123 related articles for article (PubMed ID: 27746118)
81. HES1 Promotes Colorectal Cancer Cell Resistance To 5-Fu by Inducing Of EMT and ABC Transporter Proteins.
Sun L; Ke J; He Z; Chen Z; Huang Q; Ai W; Wang G; Wei Y; Zou X; Zhang S; Lan P; Hong C
J Cancer; 2017; 8(14):2802-2808. PubMed ID: 28928869
[No Abstract] [Full Text] [Related]
82. Long Non-coding RNA H19 Recruits NFYB to Activate MBTD1 and Regulate Doxorubicin Resistance in Lymphoma Cells.
Feng L; Yan Q; Xu X
Mol Biotechnol; 2023 Jun; 65(6):997-1009. PubMed ID: 36434485
[TBL] [Abstract][Full Text] [Related]
83. Genome-wide analysis in human colorectal cancer cells reveals ischemia-mediated expression of motility genes via DNA hypomethylation.
Skowronski K; Andrews J; Rodenhiser DI; Coomber BL
PLoS One; 2014; 9(7):e103243. PubMed ID: 25079072
[TBL] [Abstract][Full Text] [Related]
84. Extracellular matrix proteins protect human HT1080 cells against the antimigratory effect of doxorubicin.
Fourre N; Millerot-Serrurot E; Garnotel R; Zahm JM; Bonnet N; Millot JM; Jeannesson P
Cancer Sci; 2008 Aug; 99(8):1699-705. PubMed ID: 18754886
[TBL] [Abstract][Full Text] [Related]
85. Influence of doxorubicin on gene expression and protein pattern in HeLa cells.
Bien S; Ritter CA; Kranz M; Scharf C; Steil L; Hummel M; Völker U; Cascorbi I; Kroemer HK
Int J Clin Pharmacol Ther; 2004 Nov; 42(11):640-1. PubMed ID: 15598030
[No Abstract] [Full Text] [Related]
86. Comparison of selected gene expression profiles in sensitive and resistant cancer cells treated with doxorubicin and Selol.
Dudkiewicz-Wilczyńska J; Grabowska A; Książek I; Sitarz K; Suchocki P; Anuszewska E
Contemp Oncol (Pozn); 2014; 18(2):90-4. PubMed ID: 24966790
[TBL] [Abstract][Full Text] [Related]
87. TFAP2E-DKK4 and chemoresistance in colorectal cancer.
Giovannetti E; Codacci-Pisanelli G; Peters GJ
N Engl J Med; 2012 Mar; 366(10):966; author reply 966. PubMed ID: 22397669
[No Abstract] [Full Text] [Related]
88. A literature mining-based approach for identification of cellular pathways associated with chemoresistance in cancer.
Oh JH; Deasy JO
Brief Bioinform; 2016 May; 17(3):468-78. PubMed ID: 26220932
[TBL] [Abstract][Full Text] [Related]
89. Doxorubicin resistance induces IL6 activation in the colon cancer cell line LS180.
Li XY; Liao XF; Wang HB; Zhang J
Oncol Lett; 2018 Nov; 16(5):5923-5929. PubMed ID: 30344742
[TBL] [Abstract][Full Text] [Related]
90. Stepwise molecular mechanisms responsible for chemoresistance in bladder cancer cells.
Mun JY; Baek SW; Jeong MS; Jang IH; Lee SR; You JY; Kim JA; Yang GE; Choi YH; Kim TN; Chu IS; Leem SH
Cell Death Discov; 2022 Nov; 8(1):450. PubMed ID: 36344487
[TBL] [Abstract][Full Text] [Related]
91. Corrigendum to: SIAH1/ZEB1/IL-6 axis is involved in doxorubicin (Dox) resistance of osteosarcoma cells.
Han X; Liu F; Zhang C; Ren Z; Li L; Wang G
Biol Chem; 2019 Aug; 400(9):1241. PubMed ID: 31216262
[No Abstract] [Full Text] [Related]
92. Understanding Cancer's Defense against Topoisomerase-Active Drugs: A Comprehensive Review.
Sharma NK; Bahot A; Sekar G; Bansode M; Khunteta K; Sonar PV; Hebale A; Salokhe V; Sinha BK
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398072
[TBL] [Abstract][Full Text] [Related]
93. Mir-153-3p Modulates the Breast Cancer Cells' Chemosensitivity to Doxorubicin by Targeting KIF20A.
Rahman KU; Yang S; Azam N; Yuan Z; Yu J; Zhao C; Feng B
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980610
[TBL] [Abstract][Full Text] [Related]
94. Cytotoxic and Radiosensitizing Effects of Folic Acid-Conjugated Gold Nanoparticles and Doxorubicin on Colorectal Cancer Cells.
Heshmatian B; Behrouzkia Z; Mohammadian M; Moradi Z; Mohammadi Z; Zohdi Aghdam R
Adv Pharm Bull; 2022 Aug; 12(4):772-779. PubMed ID: 36415636
[No Abstract] [Full Text] [Related]
95. Co-Treatment of Caco-2 Cells with Doxorubicin and Gold Nanoparticles Produced from
Aboyewa JA; Sibuyi NRS; Goboza M; Murtz LA; Oguntibeju OO; Meyer M
Nanomaterials (Basel); 2022 Nov; 12(21):. PubMed ID: 36364694
[TBL] [Abstract][Full Text] [Related]
96. Apigenin alleviates resistance to doxorubicin in breast cancer cells by acting on the JAK/STAT signaling pathway.
Maashi MS; Al-Mualm M; Al-Awsi GRL; Opulencia MJC; Al-Gazally ME; Abdullaev B; Abdelbasset WK; Ansari MJ; Jalil AT; Alsaikhan F; Shalaby MN; Mustafa YF
Mol Biol Rep; 2022 Sep; 49(9):8777-8784. PubMed ID: 35804214
[TBL] [Abstract][Full Text] [Related]
97. Camel Urine Promotes Sensitization to Doxorubicin by Inhibiting Epithelial-Mesenchymal Transition and Modulating NF-κB-Snail Signaling Pathway in Breast Cancer Cells.
Al-Mutairi MS; Matar IK; Alfadli S; Al-Mutairi A
Asian Pac J Cancer Prev; 2021 Dec; 22(12):4017-4029. PubMed ID: 34967584
[TBL] [Abstract][Full Text] [Related]
98. Nongenotoxic ABCB1 activator tetraphenylphosphonium can contribute to doxorubicin resistance in MX-1 breast cancer cell line.
Kubiliute R; Januskeviciene I; Urbanaviciute R; Daniunaite K; Drobniene M; Ostapenko V; Daugelavicius R; Jarmalaite S
Sci Rep; 2021 Mar; 11(1):6556. PubMed ID: 33753859
[TBL] [Abstract][Full Text] [Related]
99. Mechanisms of tRNA-derived fragments and tRNA halves in cancer treatment resistance.
Zhang Y; Qian H; He J; Gao W
Biomark Res; 2020; 8():52. PubMed ID: 33072328
[TBL] [Abstract][Full Text] [Related]
100. DUSP4 promotes doxorubicin resistance in gastric cancer through epithelial-mesenchymal transition.
Kang X; Li M; Zhu H; Lu X; Miao J; Du S; Xia X; Guan W
Oncotarget; 2017 Nov; 8(55):94028-94039. PubMed ID: 29212207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
